Tag: AML

Oncotarget News

Oncotarget

Case for Inflammatory Memory for Hematopoietic Stem and Progenitor Cells in AML Niche

September 5, 2024

In this research perspective, we discuss recent work from our lab describing an active role of HSPCs in AML and the potential implications.”BUFFALO, NY- September 5, 2024 – A new... read more

Figure 6: Effects of various drug combinations on molecular markers of apoptosis in patient-derived cell samples.

Oncotarget

ABT199/Venetoclax Synergism With Thiotepa in Acute Myeloid Leukemia (AML) Cells

March 25, 2024

the combination of ABT199/venetoclax and Thio enhances the cytotoxicity of (Flu+Clad+Bu) in AML cell lines and leukemia patient-derived cell samples.”BUFFALO, NY- March 25, 2024 – A new... read more

Oncotarget

Reductive Carboxylation of Glutamine as a Potential Target in AML

January 16, 2024

Identification and validation of novel and targetable metabolic weaknesses in AML is ongoing.”BUFFALO, NY- January 16, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on December... read more

Oncotarget

Oncotarget | MK256 a Novel CDK8 Inhibitor With Potent Antitumor Activity in AML Through Downregulation of STAT Pathway

November 10, 2022

In summary, our study shows that MK256, a potent and selective CDK8 inhibitor, is an effective negative STAT pathway regulator both in vitro and in vivo in AML.”BUFFALO, NY-... read more

Oncotarget

Testimonial: Dr. Michael Andreeff

November 5, 2021

Below is a transcript of the testimonial by Dr. Michael Andreeff, from the University of Texas MD Anderson Cancer Center, about his experience publishing the... read more

To the top ↑ Up ↑